Advances in Cancer Immunotherapy™ - Charleston, SC

When:  Feb 24, 2018 from 8:00 AM to 2:00 PM (ET)

Organizers: sitc_log_color.png

Zihai Li, MD, PhD – MUSC Hollings Cancer Center
Michele Taffaro-Neskey, PA-C MUSC Hollings Cancer Center


Registration Rates

Share with your colleagues

Program Registration

Advance online registration for the Advances in Cancer Immunotherapy™ education program in Charleston is NOW AVAILABLE.

Advance registration will close on February 19, 2018 at 5 p.m. ET, and onsite registration will be available.

A PDF version of the registration form can be found here.

Program Agenda

Online Preprogram Course: Introduction to Immunology

Participation in this online preprogram course is strongly recommended as it contains information that will not be covered at the program on February 9. This interactive course provides foundational knowledge that is necessary for understanding cancer immunotherapy content that will be discussed at the in-person program. Please click HERE to access the course.

February 24, 2018  Program
5.5 AMA PRA Category 1 Credits™ Click here for more detailed CME, CNE and CPE information and program objectives.

Presentations include time for Audience Response System (ARS)-assisted audience interaction as well as general question and answer time.

7:00 – 8:00 a.m.

Check-in, Onsite Registration and Networking

Part A: Introduction to Incorporating Immunotherapy Into Clinical Practice

Session I: From Basic Principles to Clinical Applications of Cancer Immunotherapy

8:00 – 8:05 a.m.

Welcome, Introduction, and Pretest Questions by the Society for Immunotherapy of Cancer

8:05 – 8:35 a.m.

Basic Principles of Cancer Immunotherapy
Eric Bartee, PhD – Medical University of South Carolina

8:35 – 8:55 a.m.

Immunotherapy for the Treatment of Melanoma
Chrystal Paulos, PhD – MUSC Hollings Cancer Center

8:55 – 9:15 a.m.

Immunotherapy for the Treatment of Lung Cancer
John Wrangle, MD – MUSC Hollings Cancer Center

9:15 – 9:35 a.m.

Immunotherapy for the Treatment of Genitourinary Cancers
Todd Gourdin, MD – MUSC Hollings Cancer Center

9:35 – 9:55 a.m

Immunotherapy for the Treatment of Hematologic Malignancies
Zihai Li, MD, PhD – MUSC Hollings Cancer Center

9:55 – 10:15 a.m

Immunotherapy for the Treatment of Head and Neck Cancers
David Neskey, MD – MUSC Hollings Cancer Center

10:15 – 10:25 a.m


Session II: Overcoming Barriers to Incorporating Immunotherapy Into Community Practice

10:25 – 10:30 a.m.

Information About the Society for Immunotherapy of Cancer Resources

10:30 – 11:00 a.m.

Effective Practices for Incorporating Immunotherapy Into Hospital Operations

11:00 – 11:30 a.m.

Coverage and Reimbursement Challenges and Strategies

11:30 – 11:35 a.m.

Take-Home Points for Part A

11:35 a.m. – noon


Part B: Immune-Related Adverse Event (irAE) Management

noon – 12:20 p.m.

Mechanisms of Immune-Related Adverse Events
Mark Rubinstein, MD, FACS – Otolaryngology Associates, P.C.

12:20 – 12:50 p.m.

Nursing Perspective on irAEs: Patient Education, Monitoring and Management
Michelle Taffaro-Neskey, PA-C – MUSC Hollings Cancer Center

12:50 – 1:20 p.m.

Management and Mitigation of irAEs for Immunotherapy Prescribers
John Kaczmar, MD – MUSC Hollings Cancer Center

1:20 – 1:50 p.m.

Identification and Management of Immune-Related Adverse Events in the Emergency Setting

1:50 – 1:55 p.m.

Posttest Questions by the Society for Immunotherapy of Cancer

1:55 – 2:00 p.m.

Take-Home Points for Part B and Closing Remarks

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE- and CNE-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these six-hour programs will facilitate understanding of:

  • The rationale for common approaches to immunotherapy
  • The clinical applications of immunotherapy for disease states with FDA-approved treatments (melanoma, and lung, genitourinary, hematologic, and head and neck cancers)
  • Operational and reimbursement barriers to implementing immunotherapy in a community setting and strategies to overcome them
  • The identification and management of immune-related adverse events from the nursing and prescriber perspective in the clinic and emergency settings

Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through two post-program webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice. Breakfast and lunch will be served at the live portion of this event.

For more information, including program objectives, click here.

This program is presented in collaboration with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC).      




The 2017 - 2016 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants
from Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Incyte Corporation, Merck & Co., Inc. and Prometheus Laboratories Inc.

#ClinicalTrials #CNE #Clinician #Collaboration #SkinCancer #PresentationSlides #TherapeuticCancerVaccines #InpersonEvent #Toxicities #AlliedHealth #Industry #ImmunomodulatingDrugs #CombinationTherapy #LungCancer #HeadandNeckCancer #Pharmacist #Nurse #SITC #2017 #Oncologist #ImmuneCheckpointInhibitors #AdverseEvents #AdvancesinCancerImmunotherapyACI #HematologicMalignancies #CollaborativeEvent #Biomarkers #Introductory #CME #GenitourinaryCancer #CPE


Charleston Marriott
170 Lockwood Boulevard
Charleston, SC, 29403